Titre :

Analysis of risk factors for recurrence in cervical cancer patients after fertility-sparing treatment: The FERTISS retrospective multicenter study.

Auteur(s) :

Sláma, J. [Auteur]
Runnebaum, I. B. [Auteur]
Scambia, G. [Auteur]
Angeles, M. A. [Auteur]
Bahrehmand, K. [Auteur]
Kommoss, S. [Auteur]
Fagotti, A. [Auteur]
Narducci, Fabrice [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
Matylevich, O. [Auteur]
Holly, J. [Auteur]
Martinelli, F. [Auteur]
Koual, M. [Auteur]
Kopetskyi, V. [Auteur]
El-Balat, A. [Auteur]
Corrado, G. [Auteur]
Căpîlna, M. E. [Auteur]
Schröder, W. [Auteur]
Novàk, Z. [Auteur]
Shushkevich, A. [Auteur]
Fricová, L. [Auteur]
Cibula, D. [Auteur]

Titre de la revue :

American Journal of Obstetrics and Gynecology

Nom court de la revue :

Am J Obstet Gynecol

Date de publication :

2022-11-26

ISSN :

1097-6868

Mot(s)-clé(s) en anglais :

cervical cancer
conization
fertility-sparing treatment
recurrence
trachelectomy

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Background Fertility-sparing treatment in patients with cervical cancer should, in principle, follow identical algorithms to that in patients without future reproductive plans. In recent years, a trend toward nonradical ...
Lire la suite >Background Fertility-sparing treatment in patients with cervical cancer should, in principle, follow identical algorithms to that in patients without future reproductive plans. In recent years, a trend toward nonradical procedures, such as conization or simple trachelectomy, has become apparent in medical literature, because of their associations with better pregnancy outcomes. However, the published reports included small numbers of patients and heterogenous treatment strategies to ascertain the safety of such approaches. Objective This study aimed to collect multi-institutional data regarding the oncological outcomes after fertility-sparing treatment in patients with cervical cancer and to identify prognostic risk factors, including the influence of the radicality of individual cervical procedures. Study Design Patients aged 18 to 40 years with International Federation of Gynecology and Obstetrics 2018 stage IA1 with positive lymphovascular space invasion or ≥IA2 cervical cancer who underwent any type of fertility-sparing procedure were eligible for this retrospective observational study, regardless of their histotype, tumor grade, and history of neoadjuvant chemotherapy. Associations between disease- and treatment-related characteristics with the risk of recurrence were analyzed. Results A total of 733 patients from 44 institutions across 13 countries were included in this study. Almost half of the patients had stage IB1 cervical cancer (49%), and two-thirds of patients were nulliparous (66%). After a median follow-up of 72 months, 51 patients (7%) experienced recurrence, of whom 19 (2.6%) died because of the disease. The most common sites of recurrence were the cervix (53%) and pelvic nodes (22%). The risk of recurrence was 3 times higher in patients with tumors >2 cm in size than in patients with smaller tumors, irrespective of the treatment radicality (19.4% vs 5.7%; hazard ratio, 2.982; 95% confidence interval, 1.383–6.431; P=.005). The recurrence risk in patients with tumors ≤2 cm in size did not differ between patients who underwent radical trachelectomy and patients who underwent nonradical (conization and simple trachelectomy) cervical procedures (P=.957), regardless of tumor size subcategory (<1 or 1–2 cm) or lymphovascular space invasion. Conclusion Nonradical fertility-sparing cervical procedures were not associated with an increased risk of recurrence compared with radical procedures in patients with tumors ≤2 cm in size in this large, multicenter retrospective study. The risk of recurrence after any type of fertility-sparing procedure was significantly greater in patients with tumors >2 cm in size.Lire moins >

Comité de lecture :

Oui

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192

Date de dépôt :

2023-12-13T03:57:48Z
2024-01-22T10:44:40Z